<div id="readability-page-1"><p><span>Vera Therapeutics (NASDAQ:VERA - Get Free Report)</span> had its price target lifted by Bank of America  from $48.00 to $66.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has a &#34;buy&#34; rating on the stock. Bank of America's price objective indicates a potential upside of 29.07% from the company's previous close.</p><div><p><span></span><span>Get <strong>Vera Therapeutics</strong> alerts:</span></p></div><ul><li>Analysts Can't Get Enough of These Little-Known Biopharma Stocks</li></ul><p>A number of other analysts have also issued reports on VERA. Wedbush boosted their price target on Vera Therapeutics from $23.00 to $33.00 and gave the company a &#34;neutral&#34; rating in a report on Thursday, December 11th. Evercore ISI lifted their price objective on Vera Therapeutics from $75.00 to $97.00 and gave the company an &#34;outperform&#34; rating in a report on Monday, December 8th. Pivotal Research  set a $73.00 target price on shares of Vera Therapeutics in a report on Friday, December 5th. The Goldman Sachs Group boosted their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the company a &#34;buy&#34; rating in a report on Friday. Finally, JPMorgan Chase &amp; Co. dropped their price objective on shares of Vera Therapeutics from $99.00 to $96.00 and set an &#34;overweight&#34; rating on the stock in a research note on Friday. Ten investment analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has issued  a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $74.83.</p><p><b>Check Out Our Latest Report on Vera Therapeutics</b></p><h2>Vera Therapeutics Trading Up 7.2%</h2><p>NASDAQ VERA traded up $3.45 during trading on Friday, hitting $51.14. The stock had a trading volume of 560,419 shares, compared to its average volume of 1,429,069. Vera Therapeutics has a one year low of $18.53 and a one year high of $51.19. The stock has a 50 day simple moving average of $33.47 and a 200 day simple moving average of $27.17. The stock has a market capitalization of $3.27 billion, a price-to-earnings ratio of -12.82 and a beta of 1.21. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. </p><p>Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same period in the previous year, the firm posted ($0.85) earnings per share.  Sell-side analysts predict that  Vera Therapeutics will post -2.89 earnings per share for the current year. </p><h2>Insider Buying and Selling at Vera Therapeutics</h2><p>In other Vera Therapeutics news, Director Patrick G. Enright acquired 5,882 shares of the stock in a transaction dated Thursday, December 11th. The stock was purchased at an average price of $42.50 per share, with a total value of $249,985.00. Following the transaction, the director directly owned 5,882 shares of the company's stock, valued at $249,985. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Joseph R. Young sold 15,000 shares of the company's stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the transaction, the senior vice president directly owned 47,839 shares in the company, valued at $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own  16.30% of the company's stock. </p><h2>Institutional Investors Weigh In On Vera Therapeutics</h2><p>Institutional investors and hedge funds have recently modified their holdings of the company. Bollard Group LLC purchased a new stake in shares of  Vera Therapeutics during the second quarter worth about $1,509,000.  Trexquant Investment LP increased its stake in  Vera Therapeutics by 187.1% during the 1st quarter. Trexquant Investment LP now owns 62,777 shares of the company's stock worth $1,508,000 after buying an additional 40,913 shares in the last quarter.  Dynamic Technology Lab Private Ltd acquired a new position in shares of  Vera Therapeutics during the first quarter valued at approximately $326,000.  Hudson Bay Capital Management LP purchased a new position in shares of  Vera Therapeutics in the second quarter valued at approximately $7,044,000.  Finally, American Century Companies Inc. boosted its stake in shares of  Vera Therapeutics by 89.3% in the second quarter. American Century Companies Inc. now owns 714,428 shares of the company's stock worth $16,832,000 after acquiring an additional 336,978 shares during the last quarter. Institutional investors and hedge funds own  99.21% of the company's stock. </p><h2>About Vera Therapeutics</h2> (Get Free Report)<p>Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body's own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.  </p><p>Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Vera Therapeutics</li><li>How to Read Stock Charts for Beginners</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li><li>Growth Stocks: What They Are, What They Are Not</li><li>META Rises Amid Tech Decline, Trump's AI Order Praised By Analyst</li><li>Top Biotech Stocks: Exploring Innovation Opportunities</li><li>TL;DR: Why Reddit is the New Growth Stock to Beat</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VkVSQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Vera Therapeutics Right Now?</h2><p>Before you consider Vera Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vera Therapeutics wasn't on the list.</p><p>While Vera Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

VERA

<p>Bank of America raised its price target for Vera Therapeutics from $48 to $66, maintaining a "buy" rating, indicating a potential 29.07% upside. Other analysts also adjusted their targets, with a consensus "Moderate Buy" rating and an average target of $74.83. Vera's stock rose 7.2% to $51.14, with a market cap of $3.27 billion. Insider trading activities were noted, with a director buying shares and an SVP selling shares. Institutional investors have also modified their holdings in the company.</p>

Vera Therapeutics (NASDAQ:VERA) Stock Price Expected to Rise, Bank of America Analyst Says